<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18430">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060110</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-12-9492-IG-CTIL</org_study_id>
    <nct_id>NCT02060110</nct_id>
  </id_info>
  <brief_title>MADIT-CRT LONG-TERM INTERNATIONAL FOLLOW-UP REGISTRY - EUROPE</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Israeli Association for Cardiovascular Trials - IACT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry is designed to determine the long-term mortality and morbidity benefit as a
      result of Cardiac Resynchronization Therapy with Defibrillation (CRT-D) vs. Implantable
      Cardioverter Defibrillator (ICD) therapy in the MADIT-CRT study patient population. The
      registry will collect data on patients that previously participated at MADIT-CRT sites
      within Europe through five years of participation from their orginal enrollment in the
      MADIT-CRT IDE study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>36 month follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart failure event or death</measure>
    <time_frame>36 month follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>The combined end point of heart-failure or death, whichever came first.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">447</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>MADIT-CRT CRT-D</arm_group_label>
    <description>Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MADIT-CRT ICD</arm_group_label>
    <description>Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study</intervention_name>
    <arm_group_label>MADIT-CRT CRT-D</arm_group_label>
    <other_name>Boston Scientific market approved cardiac resynchronization therapy defibrillators</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MADIT-CRT  ICD ONLY ARM</intervention_name>
    <arm_group_label>MADIT-CRT ICD</arm_group_label>
    <other_name>Market approved Boston Scientific implantable cardioverter defibrillators</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The registry involves only those patients that participated in the MADIT-CRT IDE study
        within Europe.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Active patients who were enrolled in the MADIT-CRT IDE within Europe

        Exclusion Criteria:

        Patients who are unable or unwilling to comply with the protocol requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Israeli Association for Cardiovascular Trials at Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009 Oct 1;361(14):1329-38. Epub 2009 Sep 1.</citation>
    <PMID>19723701</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 9, 2014</lastchanged_date>
  <firstreceived_date>February 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Ilan Goldenberg, MD</investigator_full_name>
    <investigator_title>Director of the  Israeli Association for Cardiovascular Trials</investigator_title>
  </responsible_party>
  <keyword>CRT</keyword>
  <keyword>HEART FAILURE</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
